Breakthrough Solutions for Effective Therapies
Oncology
Anti-Cancer Solutions Targeting metastasis, failure and drug resistance
Obesity
Preventing cancers by Treating Obesity
Viral Infection
Example : targeting adipose tissue HIV reservoir and Covid19
About us
THERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patents in January 2023.
THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin, without significant genotoxic effect on normal cells and with a very high probability of reactivation of the anti-tumor immune response.
Abstract 3293: Leptin induces breast cancer metastasis through a Neuropilin-1 (NRP-1)/OBR complex
Theranovir rewards
THERANOVIR is a winner of :
- Lab-SHAKER 2017 (Genopole),
- Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif),
- HEC-Challenge+ 2019 (HEC Paris),
- Ilab 2020 (Ministry of education and research),
- Innov’up PIA 2021 (Ile-de-France region) competitions.
- NETVA Start in America 2024
Team
Zakia BELAID-SANDAL (PhD)
Co-founder-President / CEO/CSO
17 years of experience in leading and participating in oncology programs in France and abroad
3 co-invented patents
Elie MATTA (PhD)
Assistant Scientific Investigator
PhD in Oncology and Cancer Biology
Co-author of 3 publications in DNA Repair
They support us
Labels
Contact
Head Office
Pépinière, Genopole entreprise
4 rue Pierre-Fontaine
91000 Evry-Courcouronnes
Laboratory R&D
Pavillon de Recherche 1 /Niv4/p401
Institut Gustave Roussy
Cancer Campus
114 Edouard Vaillant
94800 Villejuif
contact@theranovir.com
Phone
+ 33 1 42 11 60 43